Diagonal Bio Ab Stock Current Ratio
DIABIO Stock | 0.03 0 4.98% |
Diagonal Bio AB fundamentals help investors to digest information that contributes to Diagonal Bio's financial success or failures. It also enables traders to predict the movement of Diagonal Stock. The fundamental analysis module provides a way to measure Diagonal Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Diagonal Bio stock.
Diagonal |
Diagonal Bio AB Company Current Ratio Analysis
Diagonal Bio's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Competition |
In accordance with the recently published financial statements, Diagonal Bio AB has a Current Ratio of 0.0 times. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Current Ratio (which currently averages 0.0) industry. This indicator is about the same for all Sweden stocks average (which is currently at 0.0).
Diagonal Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Diagonal Bio's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Diagonal Bio could also be used in its relative valuation, which is a method of valuing Diagonal Bio by comparing valuation metrics of similar companies.Diagonal Bio is currently under evaluation in current ratio category among its peers.
Diagonal Fundamentals
Return On Equity | -0.52 | |||
Return On Asset | -0.27 | |||
Operating Margin | (3.67) % | |||
Current Valuation | 112.69 K | |||
Shares Outstanding | 34.77 M | |||
Shares Owned By Insiders | 14.74 % | |||
Price To Book | 0.50 X | |||
Price To Sales | 3.26 X | |||
Revenue | 407 K | |||
Gross Profit | (85 K) | |||
EBITDA | (11.66 M) | |||
Net Income | (11.66 M) | |||
Book Value Per Share | 2.39 X | |||
Cash Flow From Operations | (10.94 M) | |||
Earnings Per Share | (1.83) X | |||
Market Capitalization | 21.97 M | |||
Total Asset | 36.01 M | |||
Net Asset | 36.01 M |
About Diagonal Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Diagonal Bio AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Diagonal Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Diagonal Bio AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Diagonal Stock
Diagonal Bio financial ratios help investors to determine whether Diagonal Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Diagonal with respect to the benefits of owning Diagonal Bio security.